Trials in Older Adults

Sergei Romashkan () and Laurie Ryan ()
Additional contact information
Sergei Romashkan: National Institutes of Health, National Institute on Aging
Laurie Ryan: National Institutes of Health, National Institute on Aging

Chapter 122 in Principles and Practice of Clinical Trials, 2022, pp 2397-2415 from Springer

Abstract: Abstract This chapter discusses several unique features of clinical trials in older adults such as ethics in geriatric medicine research; recruitment and retention, including barriers to participation by older adults in clinical trials; selection of outcomes that are important to this population; effects of polypharmacy and multimorbidity on trial design; time to benefit, time to harm and life expectancy; and multimodal interventions targeting numerous risk factors and/or pathways for diseases and conditions associated with aging. This chapter also discusses unique features of trials in patients with Alzheimer’s Disease (AD) and AD-related dementias (ADRD).

Keywords: Alzheimer’s Disease (AD); AD-related dementias (ADRD); Barriers to participation; Multifactorial interventions; Multimorbidity; Polypharmacy; Time to benefit; Time to harm; Universal outcomes; Older adults (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-319-52636-2_260

Ordering information: This item can be ordered from
http://www.springer.com/9783319526362

DOI: 10.1007/978-3-319-52636-2_260

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().